News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
486,314 Results
Type
Article (8173)
Company Profile (141)
Press Release (477999)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166819)
Career Advice (303)
Deals (25782)
Drug Delivery (9)
Drug Development (52878)
Employer Resources (14)
FDA (9764)
Job Trends (8585)
News (238254)
Policy (17939)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (489)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (99)
Alliances (33166)
ALS (108)
Alzheimer's disease (986)
Antibody-drug conjugate (ADC) (299)
Approvals (10410)
Artificial intelligence (334)
ASCO (165)
Autoimmune disease (220)
Automation (29)
Bankruptcy (263)
Belgium (1)
Best Places to Work (6964)
BIO (36)
Biologics (9)
BIOSECURE Act (1)
Biosimilars (114)
BioSpace Insights (18)
Biotechnology (89)
Bispecific (1)
Bladder cancer (142)
Brain cancer (31)
Breast cancer (521)
Cancer (3778)
Cardiovascular disease (226)
Career advice (242)
Career pathing (1)
CAR-T (178)
CDC (1)
CDMO (17)
Celiac Disease (1)
Cell therapy (486)
Cervical cancer (38)
Clinical research (48029)
Collaboration (1284)
Commercialization (4)
Compensation (1533)
Complete response letters (34)
COVID-19 (768)
CRISPR (64)
C-suite (808)
Cystic fibrosis (87)
Data (5853)
Denatured (4)
Depression (106)
Dermatology (68)
Diabetes (354)
Diagnostics (4218)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (160)
Drug pricing (9)
Drug shortages (2)
Duchenne muscular dystrophy (166)
Earnings (73769)
Editorial (2)
Employer branding (2)
Employer resources (15)
Events (88132)
Executive appointments (717)
FDA (12491)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (24)
Funding (947)
Gene editing (126)
Generative AI (11)
Gene therapy (332)
GLP-1 (299)
Government (952)
Grass and pollen (2)
Guidances (281)
Healthcare (9371)
Hematology (94)
HIV (55)
Huntington's disease (23)
IgA nephropathy (68)
Immunology and inflammation (108)
Immuno-oncology (61)
Indications (162)
Infectious disease (960)
Inflammatory bowel disease (128)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (261)
Interviews (41)
IPO (12389)
IRA (3)
Job creations (1969)
Job search strategy (232)
JPM (2)
Kidney cancer (16)
Labor market (2)
Layoffs (63)
Legal (5205)
Licensing (18)
Liver cancer (45)
Longevity (19)
Lung cancer (548)
Lymphoma (260)
Machine learning (29)
Management (4)
Manufacturing (564)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8671)
Medtech (8830)
Mergers & acquisitions (14452)
Metabolic disorders (727)
mRNA (63)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (227)
Neuropsychiatric disorders (41)
Neuroscience (1871)
NextGen: Class of 2026 (3149)
Non-profit (845)
Obesity (232)
Opinion (15)
Ovarian cancer (162)
Pain (177)
Pancreatic cancer (207)
Parkinson's disease (206)
Partnered (12)
Patents (501)
Patient recruitment (530)
Patient selection (2)
Peanut (32)
People (41378)
Peptides (2)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15522)
Phase 2 (21452)
Phase 3 (14482)
Pipeline (7689)
Policy (20)
Postmarket research (1559)
Preclinical (6557)
Press Release (34)
Prostate cancer (194)
Psychedelics (7)
Radiopharmaceuticals (195)
Rare diseases (590)
Real estate (3024)
Recruiting (7)
Regenerative medicine (2)
Regulatory (14972)
Reports (23)
Research institute (586)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (102)
Series A (164)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (90)
Sponsored (5)
Startups (2022)
Stomach cancer (4)
Supply chain (51)
Tariffs (1)
Vaccines (320)
Venture capital (18)
Weight loss (76)
Women's health (88)
Date
Today (1)
Last 7 days (285)
Last 30 days (1356)
Last 365 days (19048)
2026 (13650)
2025 (19288)
2024 (23032)
2023 (26606)
2022 (34661)
2021 (37222)
2020 (33455)
2019 (23256)
2018 (17460)
2017 (18765)
2016 (17917)
2015 (24247)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20426)
2010 (20332)
Location
Africa (227)
Alabama (77)
Alaska (2)
Arizona (310)
Arkansas (10)
Asia (18017)
Australia (2091)
California (12373)
Canada (3236)
China (547)
Colorado (496)
Connecticut (427)
Delaware (215)
Europe (24688)
Florida (1854)
Georgia (393)
Hawaii (3)
Idaho (46)
Illinois (726)
India (51)
Indiana (323)
Iowa (16)
Japan (424)
Kansas (103)
Kentucky (32)
Louisiana (27)
Maine (26)
Maryland (1231)
Massachusetts (8103)
Michigan (314)
Minnesota (572)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (122)
New Hampshire (60)
New Jersey (2695)
New Mexico (12)
New York (2900)
North Carolina (1316)
North Dakota (4)
Northern California (6213)
Ohio (293)
Oklahoma (14)
Oregon (16)
Pennsylvania (2296)
Puerto Rico (21)
Rhode Island (30)
South America (402)
South Carolina (78)
South Dakota (1)
Southern California (5160)
Tennessee (125)
Texas (2006)
United States (40058)
Utah (372)
Vermont (1)
Virginia (159)
Washington D.C. (38)
Washington State (958)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
486,314 Results for "seagen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Antibody-drug conjugate (ADC)
Pfizer punts Seagen ADC, further muddying value of the $43B buyout
The co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of the pharma.
September 4, 2026
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate
Pfizer scraps Seagen-developed ADC for solid tumors
Just weeks after Pfizer’s Seagen-acquired antibody-drug conjugate sigvotatug vedotin failed a Phase 3 non-small cell lung cancer study, the big pharma has quietly culled another program being developed by the ADC specialist.
July 15, 2026
·
1 min read
·
Gabrielle Masson
Lung cancer
Pfizer delivers ‘disappointing’ late-stage lung cancer data for ADC from $43B Seagen buy
Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of treatment.
June 23, 2026
·
2 min read
·
Tristan Manalac
Layoffs
Pfizer Cuts 100 From Former Seagen HQ Amid ‘Digital Enablement and Automation’ Push
The layoffs will affect employees at Pfizer’s Bothell, Washington site, which previously served as the headquarters for Seagen before being acquired by the pharma for $43 billion.
August 27, 2025
·
2 min read
·
Tristan Manalac
Policy
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys’ fees and costs plus interest awarded by the arbitrator of the party’s dispute.
June 28, 2024
·
1 min read
Deals
Pfizer Completes Acquisition of Seagen
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.
December 14, 2023
·
8 min read
Drug Development
ASCO: BMS’ Opdivo Challenges Seagen’s Adcetris with Phase III Win
Data from a new head-to-head study showed BMS’ Opdivo induced better progression-free survival among Hodgkin’s lymphoma patients than Seagen’s Adcetris.
June 5, 2023
·
2 min read
·
Tristan Manalac
Patents
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
·
2 min read
·
Tristan Manalac
Policy
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
·
2 min read
·
Tristan Manalac
Deals
Seagen Stockholders Approve Acquisition by Pfizer
Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the previously announced merger agreement under which Pfizer will acquire Seagen for $229 per share in cash.
May 30, 2023
·
4 min read
1 of 48,632
Next
